Xenetic Biosciences, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $6.6M
- Price
- $2.71
- % Change (Daily % change from the live per-ticker quote feed.)
- -6.23%
- Volume
- 17.2K
Quote data as of 7:06 AM ET
About
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Quick stats
Shares outstanding2.3M
Computed float1.9M
Float sourceUnknown
Cash runway (months)Unknown
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001534525
Websitehttps://www.xeneticbio.com
AI Summary
AI-generated1mo agostandardbullishclinical trialXenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
Xenetic Biosciences announced that its partner PeriNess received regulatory approval from the Israeli Ministry of Health to conduct an exploratory clinical study of DNase I in combination with anti-CD19 CAR T cells.
The investigator-initiated study will treat 12 patients with large B-cell lymphoma at the Tel-Aviv Sourasky Medical Center, aiming to evaluate efficacy and biomarker responses in patients with stable or progressive disease.
This follows strong preclinical data showing that DNase I enhances CAR T cell expansion and persistence by degrading cell-free chromatin and neutrophil extracellular traps in the tumor microenvironment.
Red flags
- Study is investigator-initiated and exploratory, not a pivotal Phase 3 trial sponsored by Xenetic
- Small cohort size (12 patients) limits statistical power and immediate commercial implications
- Forward-looking statements mention a strategic review process by the Board, indicating potential M&A or dissolution risk